Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies. (20th July 2018)

• Record Type: Journal Article
• Authors: Taghizadehghalehjoughi, Ali; Hacimuftuoglu, Ahmet; Cetin, Meltem; Ugur, Afife Busra; Galateanu, Bianca; Mezhuev, Yaroslav; Okkay, Ufuk; Taspinar, Numan; Taspinar, Mehmet; Uyanik, Abdullah; Gundogdu, Betul; Mohammadzadeh, Maryam; Nalci, Kemal Alp; Stivaktakis, Polychronis; Tsatsakis, Aristidis; Jung, Tae Woo; Jeong, Ji Hoon; El-Aty, AM Abd
• Is Part Of: Nanomedicine. Volume 13:Number 13(2018)
• Page Start: 1595
• Page End: 1606
• Publication Date: 2018-07-20
• Subjects: brain tumor -- Cavalieri's principle -- irinotecan -- metformin -- nanoparticles -- PLGA; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2017-0386
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: The present study was designed to evaluate the effects of irinotecan hydrochloride (IRI)- or metformin hydrochloride (MET)-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for the treatment of glioblastoma multiforme using in vitro neuron and U-87 MG glioblastoma cell cultures and in vivo animal model.Methods: The cytotoxic and neurotoxic effects of pure drugs, blank NPs and MET- and IRI-loaded PLGA NPs were investigated in vitro (using methylthiazolyldiphenyl-tetrazolium bromide assay) and in vivo (using Cavalieri's principle for estimation of cancer volume).Results: 1 and 2 mM doses of MET and MET-loaded PLGA NPs, respectively, significantly reduced the volume of extracted cancer.Conclusion: Consequently, MET- and IRI-loaded PLGA NPs may be a promising approach for the treatment of glioblastoma multiforme.